gamma-Muurolene is a sesquiterpene hydrocarbon found in woody and herbaceous essential-oil profiles, including hinoki-style materials in the AromaForge archive. The strongest source support is for identity, occurrence, and terpene-biosynthesis context. Bioactivity evidence is mostly mixture-level and preclinical, with antimicrobial or anti-inflammatory signals reported for whole oils where gamma-muurolene is one notable component rather than a proven isolated active. For archive use, it is best presented as a chemistry-forward marker constituent with limited standalone pharmacology evidence.
Chemical identity and composition
PubChem lists gamma-muurolene as C15H24 with an octahydronaphthalene sesquiterpene skeleton. In the local archive it is documented at 5.71% in hinoki false cypress, which is a substantial occurrence level for a sesquiterpene hydrocarbon and supports its use as a compositional marker.
Aroma and practical use
- Use the recorded woody, dry, resinous, resin descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
hinoki occurrence
A directly readable GC analysis used in the archive lists gamma-muurolene at 5.71% in hinoki false cypress leaf oil.
Measured: major constituent occurrence
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
anaphalis monocephala antimicrobial oil
A 2009 Nat Prod Commun study reported gamma-muurolene at 10.4% in Anaphalis nubigena var. monocephala oil, while the whole oil showed antibacterial activity against E. coli and Klebsiella pneumoniae.
Measured: oil composition plus antibacterial activity
This experimental finding does not establish benefit, dose or safety in people using this blend.
patchouli tps minor product
A 2008 Planta paper functionally characterized two patchouli terpene synthases and reported gamma-muurolene among the additional minor sesquiterpenes produced in the enzyme product spectrum.
Measured: sesquiterpene product profile
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No authoritative standalone toxicology monograph, IFRA restriction, or human tolerability study for isolated gamma-muurolene was verified in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the accessible activity literature is mixture-level, copy should avoid attributing direct antimicrobial or anti-inflammatory effects to isolated gamma-muurolene.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
multiproduct sesquiterpene cyclase formation
The clearest mechanism-level evidence located is biochemical rather than pharmacological: gamma-muurolene appears as a minor product in terpene-synthase pathways that cyclize farnesyl diphosphate into multiple sesquiterpenes.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical studies for isolated gamma-muurolene were located in this pass.
- The strongest biological findings concern whole essential oils, not purified gamma-muurolene tested alone.
- Public constituent-specific dermal, inhalation, and long-term safety literature remains sparse.
- 2026-07-13 verification pass: web search for IFRA/RIFM dermal limit and sensitization data found no authoritative constituent-specific results; prior dermal_limit_pct (25) and sensitizing (true) were unsourced placeholders and have been corrected to null.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.